A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T cell (CAR-T)Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this study is to see if a new, experimental drug called JNJ-75229414 is safe and useful for treating patients with metastatic castration-resistant prostate cancer. JNJ-75229414 is a Chimeric Antigen Receptor T Cell (CAR-T) cell therapy. This is the first time that JNJ75229414 will be used in humans. In this type of treatment, your white blood cells (which are a part of the immune system) will be genetically modified to become JNJ-75229414 and used to treat your metastatic castration-resistant prostate cancer.
Mark Stein, MD
|Are you at least 18 years old?
|Have you been diagnosed with metastatic CRPC (mCRPC)?